Abstract:Objective To study the expression of cAMP-response element binding protein (CREB) in the treatment of experimental autoimmune encephalomyelitis (EAE) by Icariin (ICA), and explore the possible therapeutic mechanisms of ICA. Methods EAE was established successfully on C57BL/6 EAE mice. Mice were divided randomly into three groups (n?=?6): model control group (saline 3?ml/d gavage), ICA group (ICA 300?mg/(kg?d) gavage), and ICA plus H89 group [ICA: 300?mg/(kg?d) gavage, H89: 5?mg/(kg?d), intraperitoneal injection]. H89 is a specific blocker of protein kinase A (PKA). Six normal mice were set up as normal control group and received saline 3 ml/d gavage. Treatment was started when EAE mice was presented with severe clinical symptoms. Meanwhile, the neurological signs were evaluated on daily basis. Mice were treated once a day for five days and were sacrificed at the sixth day after treatment. The cervical enlargement of the spinal cords was separated and used to investigate the expressions of CREB by western blotting. Results The mean clinical scores were significantly reduced by the treatment of ICA (P?0.05) when compared with model control group, which was abolished by H89 treatment (P?0.05). Western blotting results revealed that the expression of CREB in the central nervous system decreased in model control group compared with normal control group (P?0.05). Treatment with ICA promoted the expressions of CREB when compared with model control group (P?0.05), which was reversed by H89 (P?0.05). Conclusions Icariin ameliorates neurological symptoms of EAE potentially due to promotion of CREB expressions in the central nervous system through PKA pathway.